August 14, 2016

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

.   .   

 

This randomized control trial of over 4000 high risk patients with Type 2 diabetes and eGFR > 30 ml/min, empagliflozin (a sodium-glucose cotransporter 2 inhibitor) when compared with placebo was associated with slower progression of kidney disease (12.7% vs 18.8% for worsening nephropathy and 1.5% vs 2.6% for doubling of serum creatinine) when added to the standard of care.  Renal replacement therapy was initiated in 0.3% of the treatment group vs 0.6% of the placebo group (55% lower relative risk).

 

Related Articles:

Chronic Kidney Disease, Clinical Nephrology, Clinical Trial Results, Diabetes, General Nephrology